When claims are drawn from these sources, they are attributed to "Omzo's published materials" or "per Omzo's Terms." FDA.gov primary sources: The FDA's public page on unapproved GLP-1 drugs, the April 30, 2026 FDA press release on the 503B Bulks List proposal, and the Federal Register notice 91 Fed
However, direct head-to-head trials are needed to confirm these findings across diverse clinical settings
operates on a contingency fee basis
The GLP-1 vision loss lawsuits primarily involve claims of nonarteritic anterior ischemic optic neuropathy (NAION), a serious eye condition that can cause sudden blurred vision or permanent vision loss
This group will be facilitated through a fat-affirming, weight stigma lens that prioritizes the demonstrated history of risk and harm associated with intentional weight-loss, including GLP-1s
You'll also get a blood test that checks for damage to the heart muscle